Replies to post #31808 on Savvy Trades and Investments

[hweb2]

That's from the company on NAII. Here's yesterday's quote from the CEO:

"I remain confident our continued investment in research, production efficiencies, sales initiatives and patent prosecution should help us achieve double digit growth in the approaching fiscal year in all our business segments."

The patent expires on the instant release version on Carnosyn. But they launched a sustained release Carnosyn last year, which has better results and less side effects. That patent lasts through 2026. I figured the high margin segment would probably be kinda flattish next year with the patent expiring. Maybe even decline. So was happy to see the comment from the CEO yesterday about double digit growth next year for ALL their segments. I actually thought there was more good than bad in yesterday's earnings release. Sure wouldn't know it looking at the stock price today!